Day after resigning, Tidmarsh now says he’ll fight exit from FDA
One day after stepping down as CDER Director, George Tidmarsh has said he will fight the investigations into his conduct and is reconsidering his decision.
One day after stepping down as CDER Director, George Tidmarsh has said he will fight the investigations into his conduct and is reconsidering his decision.
Eli Lilly has shown that Jaypirca is as good as, if not better than, Johnson & Johnson and AbbVie’s Imbruvica at shrinking certain types of
Vertex and CRISPR Therapeutics released first data on Monday showing that their landmark gene therapy Casgevy is effective in kids under 12. Casgevy was approved
Kimberly-Clark plans to acquire Kenvue in a deal worth about $48.7 billion in enterprise value. The deal, which was announced Monday morning, brings together the
Facing talc and Tylenol litigation, J&J consumer health spinout Kenvue has agreed to a takeover by consumer goods giant Kimberly-Clark.
Caribou Biosciences believes it has developed a ready-made CAR-T therapy that’s on par with currently available custom-made treatments for blood cancer, succeeding where other cell
Thousands of people from Scotland’s most deprived areas will get free weight-loss jabs in a real-world study to gauge if they can save the NHS
A Milan-based drugmaker has secured $141 million in a Series B raise backed by Amgen to develop gene therapies for two inherited retinal diseases that
For decades, the FDA has long been thought of as a steady hand of gold-standard regulatory work for the most innovative drugs in the world.
George Tidmarsh, who leads the FDA’s powerful drugs office known as CDER, has been placed on leave from the agency, according to reports. According to
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844